Full-Time

Senior Director

Clinical Operations

Confirmed live in the last 24 hours

Orbital Therapeutics

Orbital Therapeutics

51-200 employees

Develops RNA-based medicines and therapies

Biotechnology
Healthcare

Expert

Cambridge, MA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform

You match the following Orbital Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Requires a B.A./B.S. preferably in nursing, biology, biochemistry, or related areas (advanced degrees desirable) with at least 15 years of experience in clinical research operations.
  • Experience in phase I to phase III clinical studies. Global experience a plus.
  • Experience in immunology, hematology, oncology, or rare disease indications is a plus.
  • Understands and ensures adherence to SOPs, ICH/GCP, and FDA and other health authorities’ regulations, with strong understanding of inspection readiness.
  • Demonstrated knowledge and experience in the regulatory aspects of pharmaceutical development, including protocol implementation, data collection and reporting, and understands preparation of regulatory submissions.
  • Demonstrated experience in study management/monitoring, as well as working and negotiating with CROs.
  • Demonstrated project management expertise, including the leadership and development of cross functional teams.
  • Demonstrated ability to work independently with exceptional organization and attention to detail.
Responsibilities
  • Develop and execute clinical operations strategies aligned with the company’s overall goals and objectives.
  • Plan and communicate with cross-functional teams to ensure proper initiation, execution, and conduct of clinical trials and generation of high-quality clinical data.
  • Serve as a primary point of contact and resource for clinical operations activities for CROs, vendor personnel, investigator site personnel, and other team members at Orbital.
  • Collaborate with medical, regulatory, data management, biostatistics, and other functional teams to align clinical operations with overall program goals.
  • Interact and work closely with the clinical consultant to ensure proper execution of the clinical activities.
  • Provide oversight and management of CROs, consultants, vendors, and clinical sites.
  • Oversee and monitor the management of clinical studies ensuring they are conducted in compliance with the agreed study plans and all applicable regulations and requirements.
  • Monitor progress of clinical activity and report on the progress of assigned clinical trials including budget, timelines, and clinical data collection.
  • Prepare potential investigator site lists and assist with their evaluation for inclusion in the study.
  • Review and approve study-related plans generated by CROs and vendors, and ensure the documentation is in accordance with GCP regulatory requirements and consistent with the protocol for assigned studies.
  • Participate in the authoring, review and finalization of clinical study-related documents such as protocols, protocol amendments, clinical study reports (CSRs), regulatory submissions and other publications as required.
  • Coordinate the delivery of clinical trial supplies in collaboration with CRO and other team members.
  • Request and critically evaluate proposals and change orders from CROs, vendors and investigator sites (as applicable).
  • Manages escalation of study related issues and communicates as appropriate.
  • Anticipate potential study issues and to prepare contingency plans with minimal oversight.
Desired Qualifications
  • Global experience a plus.
  • Experience in immunology, hematology, oncology, or rare disease indications is a plus.

Orbital Therapeutics focuses on developing RNA-based medicines, specifically targeting areas like vaccines, immunomodulation, and protein replacement. The company utilizes RNA technology along with advanced delivery methods and data science to create a platform for a wide range of therapeutic applications. Unlike many competitors, Orbital Therapeutics does not work with small interfering RNA, allowing it to carve out a unique niche in the genetic medicine space. The goal is to enhance global health by harnessing RNA medicines to treat diseases in innovative ways that were not possible before. Revenue is generated through the sale of these RNA-based therapies to healthcare providers, who then administer them to patients.

Company Size

51-200

Company Stage

Series A

Total Funding

$262.6M

Headquarters

San Francisco, California

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Orbital secured $270 million in Series A financing for RNA medicine development.
  • Advancements in lipid nanoparticle delivery systems benefit Orbital's RNA delivery techniques.
  • Growing demand for personalized medicine aligns with Orbital's RNA-based therapy focus.

What critics are saying

  • Increased competition from companies like Moderna could challenge Orbital's market position.
  • Potential regulatory hurdles may delay RNA-based therapy product approvals.
  • Rapid technological advancements require continuous R&D investment, straining financial resources.

What makes Orbital Therapeutics unique

  • Orbital Therapeutics focuses on RNA-based medicines excluding small interfering RNA.
  • The company integrates RNA technology with data analytics and automation for drug development.
  • Orbital's leadership includes experts with over 20 years of drug discovery experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

13%
Business Wire
Sep 5th, 2024
Orbital Therapeutics Appoints Anna Dixon as Senior Vice President, Human Resources

Orbital Therapeutics appoints Anna Dixon as senior vice president, human resources.

Business Wire
Sep 3rd, 2024
Orbital Therapeutics Appoints Veteran Biopharma Leader, Ron Philip, as Chief Executive Officer

Orbital Therapeutics appoints veteran biopharma leader, Ron Philip, as chief executive officer.

Business Wire
Apr 27th, 2023
Orbital Therapeutics Secures $270 Million in Series A Financing to Unleash Full Potential of RNA Medicines

Orbital Therapeutics, a company focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease, today ann

Pharmaceutical Technology
Apr 27th, 2023
Orbital raises $270m for advancement of RNA medicines

Orbital is developing an RNA platform that can combine well-known and upcoming RNA technologies and delivery systems.

Phacilitate
Apr 27th, 2023
Orbital Therapeutics Closes $270M Series A Funding

Orbital Therapeutics aims to develop RNA-based therapeutics for various human diseases, including next-generation vaccines, immunomodulation, and protein replacement.